Biohaven (NYSE: BHVN) adds John Yetimoglu to board, grants options
Rhea-AI Filing Summary
Biohaven Ltd. appointed John Yetimoglu to its Board of Directors, effective August 6, 2026. He will serve in the director class whose term expires at the 2027 Annual Meeting of Shareholders and has been named to the Board’s Nominating and Governance Committee. The company states there is no arrangement or understanding with any other person regarding his selection, no family relationships with other directors or executive officers, and no related-party transactions involving him that require disclosure under Item 404(a) of Regulation S‑K.
Under Biohaven’s compensation policy for non‑employee directors, Mr. Yetimoglu is entitled to options to purchase common shares with an aggregate grant date fair value of $713,875, vesting 25% on grant and 25% on each of the following three anniversaries of grant, subject to his continuous service. He will also receive a $57,000 annual retainer for his service as a director and committee member.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 5.02, 9.01
2 items
Item 5.02
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers
Governance
Key personnel changes including departures, elections, or appointments of directors and executive officers.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Director option grant fair value: $713,875
Initial vesting tranche: 25%
Annual vesting tranches: 25%
+3 more
6 metrics
Director option grant fair value
$713,875
Aggregate grant date fair value of options for John Yetimoglu as a non-employee director
Initial vesting tranche
25%
Portion of director stock options vesting on the grant date
Annual vesting tranches
25%
Portion of options vesting on each of the following three anniversaries of grant
Annual director retainer
$57,000
Annual retainer for Mr. Yetimoglu’s service as a director and committee member
Director appointment effective date
August 6, 2026
Effective date of John Yetimoglu’s appointment to Biohaven’s Board
Director term expiry year
2027
Year of Annual Meeting of Shareholders when Mr. Yetimoglu’s director class term expires
Key Terms
grant date fair value, Nominating and Governance Committee, Emerging growth company, Item 404(a) of Regulation S-K
4 terms
grant date fair value financial
"options to purchase the Company’s common shares with an aggregate grant date fair value"
The grant date fair value is the estimated dollar worth of a stock-based award (such as stock options or restricted shares) at the exact moment it is given to an employee or contractor. Investors care because companies use that value to record compensation expenses and to show how much potential ownership and earnings dilution those awards could create—think of it as the price tag placed on a gift card when it is handed over so the company can report the cost now.
Nominating and Governance Committee regulatory
"appointed as a member of the Nominating and Governance Committee of the Board"
A nominating and governance committee is a group of board members tasked with choosing and evaluating directors, planning leadership succession, and setting the company’s board-related rules and ethical standards. Think of it as the company’s hiring and rule-making panel for its top overseers. Its work matters to investors because it shapes who governs the company, how leadership transitions are handled, and whether the board can effectively oversee management and protect shareholder interests.
Emerging growth company regulatory
"Emerging growth company"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Item 404(a) of Regulation S-K regulatory
"interest that are required to be reported under Item 404(a) of Regulation S-K"
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What board change did Biohaven (BHVN) disclose in this 8-K?
Biohaven appointed John Yetimoglu to its Board of Directors, effective August 6, 2026. He will serve in the director class whose term expires at the company’s 2027 Annual Meeting of Shareholders and will sit on the Nominating and Governance Committee.
What committee role will John Yetimoglu have at Biohaven (BHVN)?
John Yetimoglu has been appointed as a member of Biohaven’s Nominating and Governance Committee. This committee oversees board composition, governance practices, and director nominations as described in the company’s governance framework.
How is Biohaven (BHVN) compensating John Yetimoglu as a new director?
Under the non‑employee director compensation policy, John Yetimoglu will receive stock options with an aggregate grant date fair value of $713,875 plus a $57,000 annual retainer for his service as a director and committee member.
What are the vesting terms of John Yetimoglu’s Biohaven (BHVN) stock options?
The options granted to John Yetimoglu will vest 25% on the grant date and 25% on each of the following three anniversaries of grant, subject to his continuous service with Biohaven through each vesting date.
Was John Yetimoglu’s appointment to Biohaven’s (BHVN) board based on any prior arrangement?
Biohaven states there is no arrangement or understanding between John Yetimoglu and any other person pursuant to which he was selected as a director, indicating a standard board appointment process.